Tumor cell migration and invasion are regulated by expression of variant integrin glycoforms

Experimental Cell Research

Volumn 314, Issue 16, 2008, Pages 2941-2950

  Shaikh, Faheem M ^a   Seales, Eric C ^b   Clem, William C ^c   Hennessy, Kristin M ^a   Zhuo, Ya ^a   Bellis, Susan L ^a,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Vivo Biosciences Inc   (United States)

^c and Radiation Oncology   (United States)

Author keywords

Collagen; Colonocytes; Integrin; Metastasis; Ras; Sialic acid

Indexed keywords

BETA1 INTEGRIN; COLLAGEN TYPE 1; GLYCOSYLTRANSFERASE; RAS PROTEIN; SHORT HAIRPIN RNA; SIALIC ACID; ST6GAL I GLYCOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN VARIANT; SIALYLATION; TUMOR CELL;

EID: 51649085488     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2008.07.021     Document Type: Article

References (62)

1. Dall'Olio F., and Chiricolo M. Sialyltransferases in cancer. Glycoconj. J. 18 (2001) 841-850
2. Dall'Olio F. The sialyl-alpha2,6-lactosaminyl-structure: biosynthesis and functional role. Glycoconj. J. 17 (2000) 669-676
3. Dall'Olio F., Chiricolo M., Ceccarelli C., Minni F., Marrano D., and Santini D. Beta-galactoside alpha2,6 sialyltransferase in human colon cancer: contribution of multiple transcripts to regulation of enzyme activity and reactivity with Sambucus nigra agglutinin. Int. J. Cancer 88 (2000) 58-65
4. Kim Y.J., and Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj. J. 14 (1997) 569-576
5. Dennis J.W., Granovsky M., and Warren C.E. Protein glycosylation in development and disease. Bioessays 21 (1999) 412-421
6. Varki A., Cummings R., Esko J., Freeze H., Hart G., and Marth J. Essentials of Glycobiology (1999), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
7. Bellis S.L. Variant glycosylation: an underappreciated regulatory mechanism for beta1 integrins. Biochim. Biophys. Acta 1663 (2004) 52-60
8. Harduin-Lepers A., Vallejo-Ruiz V., Krzewinski-Recchi M.A., Samyn-Petit B., Julien S., and Delannoy P. The human sialyltransferase family. Biochimie 83 (2001) 727-737
9. Recchi M.A., Hebbar M., Hornez L., Harduin-Lepers A., Peyrat J.P., and Delannoy P. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res. 58 (1998) 4066-4070
10. Dall'Olio F., Malagolini N., and Serafini-Cessi F. Enhanced CMP-NeuAc:Gal beta 1,4GlcNAc-R alpha 2,6 sialyltransferase activity of human colon cancer xenografts in athymic nude mice and of xenograft-derived cell lines. Int. J. Cancer 50 (1992) 325-330
11. Dall'Olio F., Malagolini N., di Stefano G., Minni F., Marrano D., and Serafini-Cessi F. Increased CMP-NeuAc:Gal beta 1,4GlcNAc-R alpha 2,6 sialyltransferase activity in human colorectal cancer tissues. Int. J. Cancer 44 (1989) 434-439
12. Gessner P., Riedl S., Quentmaier A., and Kemmner W. Enhanced activity of CMP-neuAc:Gal beta 1-4GlcNAc:alpha 2,6-sialyltransferase in metastasizing human colorectal tumor tissue and serum of tumor patients. Cancer Lett. 75 (1993) 143-149
13. Skacel P.O., Edwards A.J., Harrison C.T., and Watkins W.M. Enzymic control of the expression of the X determinant (CD15) in human myeloid cells during maturation: the regulatory role of 6-sialytransferase. Blood 78 (1991) 1452-1460
14. Fukushima K., Hara-Kuge S., Seko A., Ikehara Y., and Yamashita K. Elevation of alpha2->6 sialyltransferase and alpha1->2 fucosyltransferase activities in human choriocarcinoma. Cancer Res 58 (1998) 4301-4306
15. Wang P.H., Li Y.F., Juang C.M., Lee Y.R., Chao H.T., Tsai Y.C., and Yuan C.C. Altered mRNA expression of sialyltransferase in squamous cell carcinomas of the cervix. Gynecol. Oncol. 83 (2001) 121-127
16. Kaneko Y., Yamamoto H., Kersey D.S., Colley K.J., Leestma J.E., and Moskal J.R. The expression of Gal beta 1,4GlcNAc alpha 2,6 sialyltransferase and alpha 2,6-linked sialoglycoconjugates in human brain tumors. Acta Neuropathol. (Berl) 91 (1996) 284-292
17. Recchi M.A., Harduin-Lepers A., Boilly-Marer Y., Verbert A., and Delannoy P. Multiplex RT-PCR method for the analysis of the expression of human sialyltransferases: application to breast cancer cells. Glycoconj. J. 15 (1998) 19-27
18. Lise M., Belluco C., Perera S.P., Patel R., Thomas P., and Ganguly A. Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients. Hybridoma 19 (2000) 281-286
19. Le Marer N., and Stehelin D. High alpha-2,6-sialylation of N-acetyllactosamine sequences in ras-transformed rat fibroblasts correlates with high invasive potential. Glycobiology 5 (1995) 219-226
20. Lin S., Kemmner W., Grigull S., and Schlag P.M. Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells. Exp. Cell Res. 276 (2002) 101-110
21. Zhu Y., Srivatana U., Ullah A., Gagneja H., Berenson C.S., and Lance P. Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. Biochim. Biophys. Acta 1536 (2001) 148-160
22. Harvey B.E., Toth C.A., Wagner H.E., Steele Jr. G.D., and Thomas P. Sialyltransferase activity and hepatic tumor growth in a nude mouse model of colorectal cancer metastases. Cancer Res. 52 (1992) 1775-1779
23. Bresalier R.S., Rockwell R.W., Dahiya R., Duh Q.Y., and Kim Y.S. Cell surface sialoprotein alterations in metastatic murine colon cancer cell lines selected in an animal model for colon cancer metastasis. Cancer Res. 50 (1990) 1299-1307
24. Seales E.C., Jurado G.A., Singhal A., and Bellis S.L. Ras oncogene directs expression of a differentially sialylated, functionally altered beta1 integrin. Oncogene 22 (2003) 7137-7145
25. Seales E.C., Jurado G.A., Brunson B.A., Wakefield J.K., Frost A.R., and Bellis S.L. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res. 65 (2005) 4645-4652
26. Le Marer N., Laudet V., Svensson E.C., Cazlaris H., Van Hille B., Lagrou C., Stehelin D., Montreuil J., Verbert A., and Delannoy P. The c-Ha-ras oncogene induces increased expression of beta-galactoside alpha-2,6-sialyltransferase in rat fibroblast (FR3T3) cells. Glycbiology 2 (1992) 49-56
27. Dalziel M., Dall'Olio F., Mungul A., Piller V., and Piller F. Ras oncogene induces beta-galactoside alpha2,6-sialyltransferase (ST6Gal I) via a RalGEF-mediated signal to its housekeeping promoter. Eur. J. Biochem. 271 (2004) 3623-3634
28. Heino J., Ignotz R.A., Hemler M.E., Crouse C., and Massague J. Regulation of cell adhesion receptors by transforming growth factor-beta. Concomitant regulation of integrins that share a common beta 1 subunit. J. Biol. Chem. 264 (1989) 380-388
29. Lenter M., and Vestweber D. The integrin chains beta 1 and alpha 6 associate with the chaperone calnexin prior to integrin assembly. J. Biol. Chem. 269 (1994) 12263-12268
30. Bellis S.L., Newman E., and Friedman E.A. Steps in integrin beta1-chain glycosylation mediated by TGFbeta1 signaling through Ras. J. Cell. Physiol. 181 (1999) 33-44
31. Melchiori A., Allavena G., Bohm J., Remy W., Schmidt J., Parodi S., Santi L., and Albini A. Interferons inhibit chemotaxis of transformed cells and their invasion of a reconstituted basement membrane. Anticancer Res. 7 (1987) 475-479
32. Wennerberg K., Lohikangas L., Gullberg D., Pfaff M., Johansson S., and Fassler R. Beta 1 integrin-dependent and -independent polymerization of fibronectin. J. Cell Biol. 132 (1996) 227-238
33. Wang F., Hansen R.K., Radisky D., Yoneda T., Barcellos-Hoff M.H., Petersen O.W., Turley E.A., and Bissell M.J. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J. Natl. Cancer Inst. 94 (2002) 1494-1503
34. Weaver V.M., Petersen O.W., Wang F., Larabell C.A., Briand P., Damsky C., and Bissell M.J. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137 (1997) 231-245
35. Zutter M.M., Santoro S.A., Staatz W.D., and Tsung Y.L. Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7411-7415
36. Oshita F., Kameda Y., Hamanaka N., Saito H., Yamada K., Noda K., and Mitsuda A. High expression of integrin beta1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer. Am. J. Clin. Oncol. 27 (2004) 215-219
37. Bottger T.C., Maschek H., Lobo M., Gottwohl R.G., Brenner W., and Junginger T. Prognostic value of immunohistochemical expression of beta-1 integrin in pancreatic carcinoma. Oncology 56 (1999) 308-313
38. Nikkola J., Vihinen P., Vlaykova T., Hahka-Kemppinen M., Heino J., and Pyrhonen S. Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma. Melanoma Res. 14 (2004) 29-37
39. Jonjic N., Lucin K., Krstulja M., Iternicka Z., and Mustac E. Expression of beta-1 integrins on tumor cells of invasive ductal breast carcinoma. Pathol. Res. Pract. 189 (1993) 979-984
40. Gui G.P., Wells C.A., Browne P.D., Yeomans P., Jordan S., Puddefoot J.R., Vinson G.P., and Carpenter R. Integrin expression in primary breast cancer and its relation to axillary nodal status. Surgery 117 (1995) 102-108
41. Cordes N., Seidler J., Durzok R., Geinitz H., and Brakebusch C. beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 25 (2006) 1378-1390
42. Damiano J.S., Hazlehurst L.A., and Dalton W.S. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 15 (2001) 1232-1239
43. Aoudjit F., and Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20 (2001) 4995-5004
44. Damiano J.S., and Dalton W.S. Integrin-mediated drug resistance in multiple myeloma. Leuk. Lymphoma 38 (2000) 71-81
45. Hazlehurst L.A., Valkov N., Wisner L., Storey J.A., Boulware D., Sullivan D.M., and Dalton W.S. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98 (2001) 1897-1903
46. Hazlehurst L.A., Enkemann S.A., Beam C.A., Argilagos R.F., Painter J., Shain K.H., Saporta S., Boulware D., Moscinski L., Alsina M., and Dalton W.S. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 63 (2003) 7900-7906
47. Vuoristo M., Vihinen P., Vlaykova T., Nylund C., Heino J., and Pyrhonen S. Increased gene expression levels of collagen receptor integrins are associated with decreased survival parameters in patients with advanced melanoma. Melanoma Res. 17 (2007) 215-223
48. Matsuoka T., Yashiro M., Nishimura S., Inoue T., Fujihara T., Sawada T., Kato Y., Seki S., and Hirakawa-Ys Chung K. Increased expression of alpha2beta1-integrin in the peritoneal dissemination of human gastric carcinoma. Int. J. Mol. Med. 5 (2000) 21-25
49. Kawamura T., Endo Y., Yonemura Y., Nojima N., Fujita H., Fujimura T., Obata T., Yamaguchi T., and Sasaki T. Significance of integrin alpha2/beta1 in peritoneal dissemination of a human gastric cancer xenograft model. Int. J. Oncol. 18 (2001) 809-815
50. van Kempen L.C., Rijntjes J., Mamor-Cornelissen I., Vincent-Naulleau S., Gerritsen M.J., Ruiter D.J., van Dijk M.C., Geffrotin C., and van Muijen G.N. Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma. Int. J. Cancer 122 (2008) 1019-1029
51. Fingleton B. Molecular targets in metastasis: lessons from genomic approaches. Cancer Genomics Proteomics 4 (2007) 211-221
52. Ramaswamy S., Ross K.N., Lander E.S., and Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33 (2003) 49-54
53. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., and Kinzler K.W. Genes expressed in human tumor endothelium. Science 289 (2000) 1197-1202
54. Hedlund M., Ng E., Varki A., and Varki N.M. alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res. 68 (2008) 388-394
55. Hughes P.E., Renshaw M.W., Pfaff M., Forsyth J., Keivens V.M., Schwartz M.A., and Ginsberg M.H. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 88 (1997) 521-530
56. Zhang Z., Vuori K., Wang H., Reed J.C., and Ruoslahti E. Integrin activation by R-ras. Cell 85 (1996) 61-69
57. Kinashi T., Katagiri K., Watanabe S., Vanhaesebroeck B., Downward J., and Takatsu K. Distinct mechanisms of alpha 5beta 1 integrin activation by Ha-Ras and R-Ras. J. Biol. Chem. 275 (2000) 22590-22596
58. Luo B.H., Springer T.A., and Takagi J. Stabilizing the open conformation of the integrin headpiece with a glycan wedge increases affinity for ligand. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2403-2408
59. James G., Goldstein J.L., and Brown M.S. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 4454-4458
60. Prendergast G.C., Davide J.P., Lebowitz P.F., Wechsler-Reya R., and Kohl N.E. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res. 56 (1996) 2626-2632
61. Del Villar K., Urano J., Guo L., and Tamanoi F. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors. J. Biol. Chem. 274 (1999) 27010-27017
62. Kohl N.E., Omer C.A., Conner M.W., Anthony N.J., Davide J.P., deSolms S.J., Giuliani E.A., Gomez R.P., Graham S.L., Hamilton K., Handt L.K., Hartman G.D., Koblan K.S., Kral A.M., Miller P.J., Mosser S.D., O'Neill T.J., Rands E., Schaber M.D., Gibbs J.B., and Oliff A. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1 (1995) 792-797